Stock Ratings / Health Care / LMAT / financials

XRAY (46) INSP (61) KMTS (43) ATEC (38) ⌘ Pro Terminal →

LeMaitre Vascular Inc. (LMAT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$85.27 +2.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $85.92

LeMaitre Vascular Inc. (LMAT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (72% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →

ROARABLE B • BUY Cap $1.95B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LMAT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LMAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, LeMaitre Vascular Inc. (NASDAQ: LMAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $85.27 (+2.90% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, LMAT ranks #54 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LMAT compare to XRAY and INSP in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), LMAT carries a Roarable B (74/100 RQD), trailing P/E of 33.8x, gross margin of 71.5%, and ROIC of 14.7%. By comparison, XRAY (DENTSPLY SIRONA Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B) and INSP (Inspire Medical Systems Inc.) posts a C- grade (61/100 RQD, P/E 14.2x, ROIC 6.0%, cap $2.06B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LMAT?

▼

Per LMAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001158895), LeMaitre Vascular Inc. generated $249.6M in revenue (+13.5% YoY), $57.7M in net income, and $81.3M in free cash flow against $615.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $85.92 (+0.76%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 32.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LMAT)Realized 20D OHLCV Swing Band: ±6.1%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY LMAT SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 32.6% FCF Margin ($81.3M FCF) & 71.5% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 7.30 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$80.69+0.2% Next Q

Q2 (-2Q)

Grade B-$80.82+4.5% Next Q

Q3 (-1Q)

Grade B$84.45+1% Next Q

Current

Grade B$85.27+7.3% Hist 90D α

Trajectory: B- (66) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LMAT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, LMAT faces multiple-compression risk if 33.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 69.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($81.20) or 200D SMA ($94.47) invalidates the momentum regime and cuts Target Base ($91.41) toward Bear Floor ($69.92).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LMAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LMAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LMAT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$81.3M (32.6% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $193.5M

FY24

Rev $219.9M

FY25

Rev $249.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$249.6M	71.5%	27.2%	$57.7M	$81.3M	14.7%
FY 2024	$219.9M	68.6%	23.8%	$44.0M	$44.1M	13.2%
FY 2023	$193.5M	71.5%	19%	$30.1M	$36.8M	14.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LMAT)

✓Walkthrough of LMAT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LMAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.31%⚡ TESTING RESISTANCE

2026-10-30O $85.53H $85.53L $80.03C $85.27VOL 427.4K

RES: $86.11SUP: $78.19SMA50: $81.20SMA200: $94.47

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LMAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LMAT Butterfly Map → + Track LMAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

26.1%/yr Implied 5Y Growth

vs. +13.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LMAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LMAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LMAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LMAT)

Health Care Rank #54 of 1016 ⚔️ XRAY vs LMAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LMAT vs. XRAY, INSP, KMTS, ATEC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LeMaitre Vascular Inc. (LMAT) ranks #54 by composite RQD confidence (74/100, grade B) and #268 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LMAT ACTIVE LeMaitre Vascular Inc.	B	74/100	33.8x	71.5%	14.7%	+2.90%	$1.95B	Benchmark Subject
XRAY DENTSPLY SIRONA Inc.	D	46/100	—	50.0%	-11.0%	+1.80%	$1.92B	/xray-vs-lmat →
INSP Inspire Medical Systems Inc.	C-	61/100	14.2x	85.4%	6.0%	+0.30%	$2.06B	/insp-vs-lmat →
KMTS Kestra Medical Technologies Ltd.	D-	43/100	—	51.4%	-35.0%	+2.48%	$1.82B	/kmts-vs-lmat →
ATEC Alphatec Holdings Inc.	D-	38/100	—	69.6%	-18.4%	-0.70%	$1.76B	/atec-vs-lmat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001158895

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeMaitre Vascular Inc. (LMAT) reported GAAP revenue of $249.6M (+13.5% vs. FY2024 revenue of $219.9M , and +29.0% cumulative change since FY2023) , GAAP net income of $57.7M, operating cash flow of $81.3M, and free cash flow of $81.3M (+84.1% YoY). On the balance sheet, LMAT closed FY2025 with $615.7M in total assets against $0 in total debt (Altman Z-Score: 7.30, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$249.6M	$57.7M	$81.3M	$81.3M	$615.7M	—
FY2024 (FY)	2024-12-31	$219.9M	$44.0M	$44.1M	$44.1M	$551.8M	—
FY2023 (FY)	2023-12-31	$193.5M	$30.1M	$36.8M	$36.8M	—	—

3. LMAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LMAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LMAT compare to XRAY and INSP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LMAT?

Where is LMAT trading relative to its 50-day, 200-day, and 52-week technical levels?

LMAT last traded at $85.27 (+2.90% on volume of 300,147 shares), positioning the stock +5.01% above its 50-day simple moving average ($81.20) and -9.74% below its 200-day simple moving average ($94.47). Across its 52-week range of $78.22 to $118.01, LMAT sits at the 17.7% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($80.07 to $90.47).

LMAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is LeMaitre Vascular Inc. (LMAT)?

In FY 2025 (10-K), LMAT converted $249.6M of revenue into a 71.5% gross margin, 27.2% operating margin, and $81.3M in free cash flow (32.6% FCF margin).

Direct Sub-Reports: LMAT RQD Cockpit LMAT 12M Forecast LMAT Earnings & Move LMAT Dividends & DRIP LMAT Insiders & 13F LMAT Whale Options LMAT Profit Sankey LMAT News & Why